About Us>Medical Advisory Board > Virginia Kaklamani, MD, DSc

Virginia Kaklamani, MD, DSc

Medical Oncologist, Mays Cancer Center

Headshot of Dr. Virginia Kaklamani

Highlights

  • Professor of medicine in the division of hematology/oncology at the University of Texas Health Sciences Center in San Antonio
  • Leader of the breast cancer program at the Mays Cancer Center, home to University of Texas Health San Antonio MD Anderson
  • Research interests include designing clinical trials with targeted agents
  • Has identified several genetic mutations that link obesity and breast cancer 

Connect with Dr. Kaklamani

Mays Cancer Center
featured_paragraph

Virginia Kaklamani, MD, DSc, is a professor of medicine in the division of hematology/oncology at the University of Texas Health Sciences Center in San Antonio and is the leader of the breast cancer program at the Mays Cancer Center, home to University of Texas Health San Antonio MD Anderson.

general_content

Dr. Kaklamani was head of the translational breast cancer program at Northwestern University and co-director of the cancer genetics program at the same institution. She has also served as the associate director for clinical research at University of Texas Health San Antonio.

Her research interests include designing clinical trials with targeted agents. Dr. Kaklamani has also identified several genetic mutations that link obesity and breast cancer.

 

 

quote_style_1

I still love working in the clinic, helping my patients and trying to solve their particular issues. During my residency, I cared for a large and diverse population of cancer patients, which was a fulfilling experience. And I never looked back on my decision to become an oncologist.

Dr. Virginia Kaklamani, MD, The ASCO Post

video
3_column_content

Experience & Accolades

Expertise

  • Medical Oncology, Hematology, Internal Medicine

Education

Experience

Awards and Distinctions

Professional Memberships and Board Positions

Publications

In the Media

contributions_carousel

Contributions

ESR1 mutation testing

11/27/23 | BY: Virginia Kaklamani

Over time, metastatic breast cancers treated with endocrine therapy can develop a mutation in a gene called ESR1, which may develop treatment resistance.

Read More
 | 7 Min. Read

Elacestrant

02/08/23 | BY: Virginia Kaklamani

Elacestrant (Orserdu) is a hormonal therapy used to treat metastatic breast cancer.

Read More
 | 5 Min. Read |

High-risk / Concerned

03/15/22 | BY: Virginia Kaklamani

Some people are more likely than others to be diagnosed with breast cancer. Previvor is a term that’s often used to describe people who have a high risk of developing breast cancer.

Read More
 | 16 Min. Read

Highlights from the 2021 San Antonio Breast Cancer Symposium, with Virginia Kaklamani, MD, DSc

12/15/21 | BY: Virginia Kaklamani

Virginia Kalamani, MD, DSc, co-director of the 2021 San Antonio Breast Cancer Symposium, discusses significant findings about the effectiveness of olaparib, trastuzumab deruxtecan, elacestrant, and more, and the implications for people with breast cancer.

Read More
 | 29 Min. Read

Margetuximab

02/12/21 | BY: Virginia Kaklamani

Margetuximab (Margenza) is FDA-approved for metastatic, HER2-positive breast cancer. Given with chemotherapy after two prior lines of targeted therapy.

Read More
 | 5 Min. Read |

Highlights from the 2020 San Antonio Breast Cancer Symposium

12/16/20 | BY: Virginia Kaklamani

LBBC spoke with Virginia Kaklamani, MD, DSc, about the major findings presented at the 2020 SABCS and what they mean for you.

Read More
 | 21 Min. Read